Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson’s Disease

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the conclusion of a randomized, placebo-controlled, double-blind Phase 2b (KARMET) study involving 150 patients with Parkinson’s Disease (PD).

Enterin’s lead compound, ENT-01 targets alpha-synuclein, or αS, a protein known to play a key role in the pathophysiology of PD. αS accumulates in nerve cells of the gut (enteric nerves), preventing the nerve cells from functioning properly. Orally administered ENT-01 displaces αS aggregates from nerve cell membranes as well as preventing their formation. As a result, enteric nerve cell function is restored, as is communication between gut and brain.

The Phase 2b study was a randomized, placebo-controlled, double-blind study involving 150 patients with PD and constipation. Following a two-week baseline period, patients were stratified to start at high dose or low dose depending on baseline constipation severity and randomized to receive ENT-01 or placebo. Dosing was escalated every 2-3 days and “fixed” for the remainder of the 25-day treatment period. All patients were then placed on placebo for 2 weeks, followed by a 4-week wash-out.

There were no safety or tolerability concerns (n=150). There were no deaths or drug-related serious adverse events. Adverse events were largely confined to the GI tract and self-limiting. They included nausea and diarrhea.

Efficacy analyses were performed on all patients who had received at least 7 days of medication (n=136). The primary endpoint, defined as the change in complete spontaneous bowel movement (CSBM) from baseline to the end of the 3-week treatment period was significantly better in the treatment group compared to placebo (p=0.0001). The improvement persisted 2-weeks (p=0.02) and 6-weeks (p=0.05) after discontinuation of study medication. Secondary bowel endpoints were also significantly better in the treatment group compared to placebo. These included spontaneous bowel movement (SBM; p=0.001), stool consistency (p=0.0001), ease of passage (p=0.004) and laxative use (p=0.03). Exploratory endpoints included psychosis (Scale of Positive Symptoms in PD, SAPS-PD) and dementia (Mini Mental State Examination, MMSE). 13 patients had psychotic symptoms at baseline (SAPS-PD score ≥4). In the ENT-01 group (n=6), SAPS-PD score improved by 73% by the end of the 3-week treatment period and by 82% 6-weeks after treatment discontinuation. Placebo patients (n=7) showed no improvement during treatment and worsened following treatment discontinuation. Twenty-four patients had dementia at baseline (MMSE≤26). In the ENT-01 group, MMSE score improved by 2 points during the 3-week treatment period, and by 3.5 points 6 weeks beyond the treatment period. Placebo patients improved during treatment but worsened following treatment discontinuation.

In summary, both primary and secondary bowel endpoints were met, demonstrating that even a short course of ENT-01 can restore the function of enteric nerve cells. Results from small numbers of patients suggest that ENT-01 might also improve psychosis and dementia. According to Denise Barbut, MD, FRCP, Enterin’s Co-Founder, President and CMO, “The continued improvement of bowel and neurologic symptoms for weeks beyond the brief treatment period suggests a possible disease-modifying effect.”

Michael Zasloff, MD, Ph.D., Enterin’s Co-Founder and CSO, added, “Aging itself compounds the ongoing damage caused by the accumulation of alpha-synuclein. Our preclinical studies suggest that the persistence of benefit observed with ENT-01 are a consequence of the reversal of certain aspects of the aging process.”

The KARMET study was designed to replicate earlier findings of a preceding open-label RASMET study in a placebo-controlled trial. The RASMET study had established safety, tolerability and reversal of constipation following orally administered ENT-01, and signaled improvement in neurologic endpoints including memory, mood, sleep, REM-behavior disorder, psychosis, and circadian rhythm, with persistence of benefit for several weeks beyond the brief treatment period (https://doi.org/10.1016/j.prdoa.2019.06.001).

Top-line results will be presented on a conference call by Denise Barbut, MD, FRCP, Co-Founder, President and CMO of Enterin. Stuart Isaacson, MD, and Patrik Brundin, MD, Ph.D., will share their perspectives. Please join the call on Jan. 27 at 2:30 pm EST. A link to the invitation can be found on the Enterin website along with a replay of the event.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine